Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting ROCKVILLE, Md. and

Ascentage Pharma to Present Four Promising Preclinical

Studies Demonstrating the Potential of Combination

Therapies at American Association for Cancer Research (AACR)

ROCKVILLE, Md. and SUZHOU, China, April 19,

2026 - Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical

company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs

in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR)

2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA.

These posters feature three of the Company's

drug candidates, olverembatinib (HQP1351), a novel BCR-ABL inhibitor; APG-2449, a FAK/ALK/ROS1 triple tyrosine kinase inhibitor; and APG-5918,

a PRC2/EED inhibitor.

Yifan Zhai, M.D., Ph.D., Chief Medical Officer

of Ascentage Pharma, said, "These preclinical findings reflect our continued commitment to advancing innovative therapies across

multiple cancer types. The four studies demonstrate the breadth and versatility of our pipeline, exploring the therapeutic potential of

our key assets in combination with other approved treatment options in both hematologic malignancies and solid tumors.

Notably, the research examines

olverembatinib's potential beyond its approved use in China for chronic myeloid leukemia (CML), exploring new applications in

areas such as endometrial carcinoma and mantle cell lymphoma, including combination approaches with BTK inhibitors. In addition, our

evaluation of APG-2449 in BRAF-mutant tumors, and APG-5918 in small-cell lung cancer, underscores our strategic focus on addressing

resistance mechanisms and exploring combination strategies.

These preclinical investigations are designed

to inform our clinical development strategies and complement our ongoing global registrational trials as we bring new treatment options

to patients with significant unmet medical needs."

Detailed data presented at AACR 2026 Annual Meeting

are summarized below:

Multitarget kinase inhibitor Olverembatinib

(HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma (EC)

Multikinase inhibitor Olverembatinib (HQP1351)

is efficacious and synergizes with BTK inhibitor acalabrutinib in mantle cell lymphoma (MCL) preclinical models

FAK inhibition by APG-2449 enhances the antitumor

activity of MAPK pathway blockade in BRAF V600E-mutant tumor models

Embryonic ectoderm development (EED)

inhibitor APG-5918 synergizes with topoisomerase I inhibitors in preclinical small-cell lung cancer (SCLC) models through epigenetic

priming of chemosensitivity

*Olverembatinib, APG-2449, and APG-5918 are

currently under investigation and have not been approved by the U.S. FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ:

AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company") is a global, commercial stage, integrated

biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet

medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting

key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company's first approved product, Olverembatinib,

is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP)

with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and

second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an

FDA-cleared global registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as global registrational Phase

III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company's second approved product, Lisaftoclax,

is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China's National

Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

(CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors. The Company

is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK

inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2

study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared

GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities,

Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other

relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and

Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer

Institute, Mayo Clinic, National Cancer Institute and the University of Michigan.

For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained

in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations,

beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with

the SEC, including those set forth in the sections titled "Risk factors" and "Cautionary note regarding forward-looking

statements" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections

headed "Forward-looking Statements" and "Risks Factors" in the prospectus of the Company for its Hong Kong initial

public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company's

ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or

achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking

statements contained in this presentation do not constitute profit forecast by the Company's management.

As a result of these factors, you should not rely

on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are

based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak

only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,

whether as a result of new information, future events or otherwise.

Stephanie Carrington